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Abstract
Background:  Avascular necrosis of bone (osteonecrosis) can cause structural failure and
subsequent deformation, leading to joint dysfunction and pain. Structural failure is the result of
resorption of necrotic bone during revascularization, before new bone has formed or consolidated
enough for loadbearing. Bone resorption can be reduced by bisphosphonates. If resorption of the
necrotic bone could be reduced during the revascularization phase until sufficient new bone has
formed, it would appear that structural failure could be avoided.
Methods: To test whether resorption of necrotic bone can be prevented, structural grafts were
subjected to new bone ingrowth during systemic bisphosphonate treatment in a rat model.
Results: In rats treated with alendronate the necrotic bone was not resorbed, whereas it was
almost entirely resorbed in the controls.
Conclusion:  Systemic alendronate treatment prevents resorption of necrotic bone during
revascularization. In patients with osteonecrosis, bisphosphonates may therefore prevent collapse
of the necrotic bone.
Background
Osteonecrosis is caused by insufficient circulation. This
situation can occur after trauma or be the result of other
events or conditions that can compromise circulation,
such as corticosteroid treatment, scuba diving, sickle cell
anaemia, alcoholism and pregnancy. Osteonecrosis can
lead to structural failure, with subsequent collapse and de-
formation of the bone leading to joint dysfunction and
pain. Gardeniers [1] performed a series of experiments,
where a section of the femoral head in goats was removed
and reattached using bone cement. The cement layer pre-
vented revascularization, which was verified with angiog-
raphy and histology. No collapse occurred, and
mechanical testing of the avascular segment showed no
weakening compared to vital controls. However, when a
hole was drilled through the cement layer in a second op-
eration, revascularization ocurred and collapse of the fem-
oral head segment followed. Mechanical testing
confirmed weakening of the revascularized segments.
Others have confirmed that necrotic bone retains load
bearing capacity [2], and evidence can also be found in
tools made of bone, which have been known since neo-
lithicum. Consequently the death of bone cells per se does
not cause structural failure. Rather, it is caused by the re-
sorption of necrotic bone [3][1]. Resorption is mediated
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by osteoclasts, which are of hematopoetic origin [4] and
occurs during or following the revascularization of the
necrotic tissue [3][1]. Together with the resorption there is
a healing response, with new bone formation within the
revascularized tissue.
If the bone resorption associated with osteonecrosis can
be inhibited or delayed until sufficient new bone has
formed, it would appear that structural failure and its con-
sequences could be avoided. Osteoclastic activity can be
reduced with bisphosphonates, a class of drugs in clinical
use for the treatment of osteoporosis, Paget's disease and
osteolytic metastases. Bisphosphonates bind to bone min-
eral and when bone is resorbed by osteoclasts, bisphos-
phonates are internalized and interfere with cell
metabolism which leads to apoptosis. Thus, the osteo-
clasts are targeted by the treatment.
We used a previously described rat model [5] to study
whether bisphosphonate treatment could reduce or inhib-
it the resorption of necrotic bone. During systemic treat-
ment with bisphosphonate or saline, bone was allowed to
grow into necrotic bone grafts inside a bone chamber.
This model was chosen in order to standardize the com-
position, age, size and geometry of the specimens for anal-
ysis.
Figure 1
A schematic drawing of the Bone Conduction Chamber (BCC). Frozen bone allografts are placed for 6 weeks in the chambers,
which are implanted in the proximal tibia of rats. The openings at the lower end of the chamber are placed just below the peri-
osteum. Tissue grows into these openings (arrows) and penetrates the whole of the graft. Ossification reaches about halfway
from the bottom towards the top (dashed line). From Aspenberg P, Wang J-S. Eur J Exp Musculoskel Res. 1993;2:69–74. Pub-
lished with permission from Taylor & Francis.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/19
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Methods
We used the bone conduction chamber (BCC) [5]. The
chamber consists of a titanium screw with a cylindrical in-
terior space. It is made up of two threaded half cylinders
held together by a hexagonal closed screw cap. One end of
the implant is screwed into the bone. The interior of the
chamber has a diameter of 2 mm, and is 7 mm long. There
are two bone ingrowth openings located at the bone end
of the chamber (Figure 1). Thus, the ingrowing tissues en-
ter the cylindrical space from the bone compartment. The
chamber space extends far out into the subcutaneous re-
gion and the ingrown bone-derived tissue can proliferate
in the chamber without competition with other tissues.
Ingrowing tissue, most of it bone, will fill a portion of the
chamber within 6 weeks but will not reach the far end of
the cylinder. Thus, the tissue ingrowth distance from the
holes towards the other end of the chamber can be meas-
ured as an estimate for tissue regeneration. Due to the ge-
ometry of the chamber it is easy to define areas for
histomorphometry. Placing an osteoconductive material,
such as a bone graft, in the chamber can increase the tissue
ingrowth distance [6].
Pairs of structurally intact cancellous bone grafts were ob-
tained from 18 female Sprague Dawley rats (200 g) as fol-
lows. A cylindrical 2  6 mm bone rod was resected in the
axial direction from the knee joint with a hole cutter. The
epiphysis and the growth plate were excised. The proximal
part of the graft had the most dense cancellous bone and
was later turned towards the ingrowth end of the cham-
ber. The grafts were kept sterile and frozen at -70C.
An alendronate solution was prepared by dissolvling one
tablet of alendronate 10 mg (Fosamax, MSD, Malmö,
Sweden) in 10 ml water for 1 hour under stirring and then
filtering through a sterile Millipore filter, pore size 0.2 m.
This stock solution was then diluted in saline to the de-
sired concentrations.
After thawing, the grafts were placed in bone chambers
and implanted unilaterally in 34 recipient 350 g male
Sprague Dawley rats. Subcutaneous 0.5 ml injections were
given postoperatively three days a week. A high dose
group was given alendronate at a dose of 205 g  kg-1 
day-1 (n = 10) with a control group given saline (n = 10).
A low dose group was given 4 g  kg-1  day-1 (n = 8),
with separate controls (n = 7) given saline. The animals
for the both dose group and their donors (n = 30) were
obtained from M & B (M & B A/S, P.O. box 1079, DK-
8680, Ry, Denmark). After 6 weeks, the rats were killed
and the contents of the chambers prepared for decalcified
histology with sections parallel to the long axis of the
chamber, stained with hematoxyllin and eosin.
To monitor the systemic effect of alendronate, 6 mm of
the proximal, unoperated tibial metaphyses was cut at a
right angle to the long axis of the bone and weighed be-
fore and after ashing at 1000C for 24 hours in all rats.
Evaluation
For each specimen, 3 sections, each 0.3 mm apart, were
studied. All sections were blinded for identity and evalu-
ated in random order. The evaluation was done by manu-
al point counting of an area of interest ranging from the
bottom of the chamber (at the ingrowth end) to the fron-
tier of the advancing new bone formation. The area of in-
terest comprised the central third of the specimen, so that
the bone close to the titanium side walls was not includ-
ed. The total number of points, points covering bone in
general and points covering new living bone were count-
ed. The distinction between graft bone and new bone was
based on matrix staining (which is paler and more uneven
in the graft), presence of osteocytes and trabecular shape.
On average 366 points were counted per specimen. In a
previous similar experiment, the same person repeated
the point counting after one year. The measurement error
(sd) was found to be 6 percent units for graft bone, 6 per-
cent units for for new bone, and 3 percent units for bone
in general [7]. The bone ingrowth distance was measured
with computer-aided methods as described previously
[6]. For all measurements, data from the 3 segments were
averaged to form one value per graft. Statistical analysis
was then done with Mann-Whitney U-test. Institutional
guidelines for the treatment and care of experimental ani-
mals were followed.
Results
One animal was lost before harvest due to postoperative
complications. In all the others, the histological analysis
showed that soft tissue had invaded the whole grafts. New
bone had formed a bone ingrowth frontier halfway
through the graft. In the controls the grafts appeared re-
sorbed behind this frontier, so that a large marrow cavity
had formed behind the frontier, with haematogenous
bone marrow (Fig 2A). In contrast, the grafts in rats treat-
ed with the high alendronate dose remained intact, and
new bone lined the graft trabeculae, leaving only little
space for haematogenous marrow (Fig 2B). The difference
in bone density was clearly visible to the naked eye. Grafts
in rats treated with the low alendronate dose were more
similar in appearance to the controls with resorption of
the graft and marrow cavity formation but also some areas
with denser bone comprising both graft bone and newly
formed bone.
In specimens treated with the high dose alendronate,
there was no difference in the distance advanced by the
bone ingrowth frontier compared to controls (alendro-
nate 2.8 mm. sd 1.1, control 2.5 mm. sd 1.0). Of the spaceBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/19
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behind the bone ingrowth frontier, 70% (sd 18) consisted
of graft or host bone, whereas in the controls there was
27% (sd 13) (p = 0.0002). About half of the bone in the
alendronate treated specimens was new living bone that
had formed upon the surfaces of the remaining graft
trabecula. Thus, host bone comprised 37% (sd 15) of the
total volume. In the controls it was 19% (sd 9)(p = 0.005;
table 1).
In rats treated with the low dose of alendronate, graft and
host bone content was 29% (sd 11) and in the controls
18% (sd 9, p = 0.049). Host bone comprised 24% (sd 9)
of the total volume and in the controls 15% (sd 8) (n.s.).
Again, there was no difference in the bone ingrowth dis-
tance (alendronate 2.11 mm sd 0.5, controls 2.07 mm sd
0.5).
In a previous study the bone content of unimplanted
grafts was 38% (sd 10) [7]. This is similar to the remaining
graft content of the high dose alendronate treated speci-
mens, which was 34% (sd 5), with controls containing
8% (sd 4) (p = 0.0002). In the low dose alendronate spec-
imens less of the grafts remained, 5% (sd 2), and in the
controls 3% (sd 3)(p = 0.037). (Table 1)
All alendronate treated rats had higher ashweight than
their controls. This difference was more pronounced in
the high dose group (alendronate treated 136.3 mg s.d.
10, controls 57.3 mg s.d. 3, p = 0.0002) than in the low
dose group (alendronate treated 86.7 mg s.d. 9, controls
60.6 mg s.d. 4, p = 0.0012).
Discussion
Structural failure associated with osteonecrosis is caused
by resorption of the necrotic bone [3], [1]. If bone resorp-
tion could be avoided during revascularization and for-
mation of new bone, structural failure and collapse could
possibly also be avoided. In an uncontrolled clinical
study, Agarwala et al treated 16 patients with avascular
necrosis of the hip with alendronate and found improve-
ment in pain, disability and function compared to the ex-
pected natural history of the disease, and MRI remained
stable [8]. Although the results are interesting, the lack of
a control group limits the conclusions possible to draw
from that study and the authors states that the beneficial
action of alendronate in avascular necrosis of the hip is
not clear. It could be hypothesised that alendronate pre-
vented structural failure, deformation and subsequently
pain. In the present study, histological evaluation showed
that resorption of a necrotic bone graft during revascular-
isation and bone ingrowth was prevented with systemic
bisphosphonate treatment.
Allografts were used as a model for necrotic, autologous
bone. The strain of Sprague-Dawley rats used for the high
dose group is, however, inbred to such an extent that no
differences can be detected in the incorporation of auto-
versus allografts in this model [9]. Theoretically, it could
be assumed that also after freezing and thawing, allografts
are more immunogenic than autologous bone and more
prone to resorption. Since we wanted to study whether it
is possible to reduce bone resorption during revasculariza-
tion, such an increased tendency to resorption would ne-
cessitate an even greater protective effect of alendronate in
this model.
This study was performed in two phases. First, we tested
the principal possibility, by using a high alendronate
dose. When this experiment yielded a positive response,
we tested whether also a lower dose, at the level of oste-
oporosis treatment, could be effective.
In humans, the oral alendronate dose recommended for
use against osteoporosis is 10 mg daily. Due to the low
gastrointestinal uptake of about 0.6%, this would corre-
spond to an injection of 1 g  kg-1  day-1. In this study,
the low dose group received 4 g alendronate  kg-1  day-
1, a difference corresponding to the difference in metabol-
ic rate. The alendronate dose in the high dose group was
50 times higher. Both the bisphosphonate treated groups
in this study showed less bone resorption than their re-
spective controls, measurable as increased total bone con-
Figure 2
(A) Section of a graft in a control specimen. Bone ingrowth
has ocurred from the lower end of the picture and upwards.
The bone formation frontier has reached roughly halfway
through the graft (arrows). Behind the frontier a marrow
cavity has formed, and inside the cavity the graft is almost
entirely resorbed. (B) Section of a graft in a rat treated with
the high dose of alendronate. The ossification has reached
the same distance (arrows), but the graft is not resorbed.
Hematoxylin Eosin, bar lengths 1 mm.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/19
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tent and graft bone content. However, in the low dose
group this difference was less pronounced.
We also found a significant increase in host bone forma-
tion by alendronate in the high dose group. In a previous
chamber study, in which grafts were pre-treated with top-
ical alendronate, we also saw this effect: new bone forma-
tion was increased in alendronate treated specimens [7].
Bone ingrowth into the chambers is enhanced by the pres-
ence of a structural bone graft [6]. Thus, the increased
bone formation could be explained by a "scaffolding" ef-
fect: if the graft is preserved, as in the treated groups, there
are more bone graft surfaces on which new bone forma-
tion can occur.
Another explanation for the increase in new bone forma-
tion seen in alendronate treated groups would be a direct
effect of alendronate stimulating new bone formation.
There are reports of osteoblastic stimulation by bisphos-
phonates in vitro [10] and in vivo effects upon osteoblasts
have been suggested [11].
Conclusions
In conclusion, systemic bisphosphonate treatment can re-
duce the resorption of necrotic bone. This could prove
useful in clinical situations, for example as a treatment to
reduce the risk of structural failure and collapse after os-
teonecrosis. Although high dose parenteral treatment may
become necessary for full effect, also lower perorally ad-
ministered doses appeared to be of some value.
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Table 1: 
total bone volume host bone volume graft bone volume
alendr, high dose 70% (sd 18) 37% (sd 15) 34% (sd 5)
contr, high dose 27% (sd 13) 19% (sd 9) 8% (sd 4)
(p = 0.0002) (p = 0.005) (p = 0.0002)
alendr, low dose 29% (sd 11) 24% (sd 9) 5% (sd 2)
contr, low dose 18% (sd 9) 15% (sd 8) 3% (sd 3)
(p = 0.049) n.s. (p = 0.037)
not implanted grafts (ref [7]) 38% (sd 10)